Qi Liu1, Tracy S A Underwood2, Jong Kung2, Meng Wang1, Hsiao-Ming Lu2, Harald Paganetti2, Kathryn D Held1, Theodore S Hong1, Jason A Efstathiou1, Henning Willers3. 1. Laboratory of Cellular and Molecular Radiation Oncology, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. 2. Division of Radiation Physics, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. 3. Laboratory of Cellular and Molecular Radiation Oncology, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: hwillers@mgh.harvard.edu.
Abstract
PURPOSE: Clinical proton beam therapy has been based on the use of a generic relative biological effectiveness (RBE) of ∼1.1. However, emerging data have suggested that Fanconi anemia (FA) and homologous recombination pathway defects can lead to a variable RBE, at least in vitro. We investigated the role of SLX4 (FANCP), which acts as a docking platform for the assembly of multiple structure-specific endonucleases, in the response to proton irradiation. METHODS AND MATERIALS: Isogenic cell pairs for the study of SLX4, XPF/ERCC1, MUS81, and SLX1 were irradiated at the mid-spread-out Bragg peak of a clinical proton beam (linear energy transfer 2.5 keV/μm) or with 250 kVp x-rays, and the clonogenic survival fractions were determined. To estimate the RBE of the protons relative to cobalt-60 photons (Co60Eq), we assigned a RBE(Co60Eq) of 1.1 to x-rays to correct the physical dose measured. Standard DNA repair foci assays were used to monitor the damage responses, and the cell cycle distributions were assessed by flow cytometry. The poly(ADP-ribose) polymerase inhibitor olaparib was used for comparison. RESULTS: Loss of SLX4 function resulted in an enhanced proton RBE(Co60Eq) of 1.42 compared with 1.11 for wild-type cells (at a survival fraction of 0.1; P<.05), which correlated with increased persistent DNA double-strand breaks in cells in the S/G2 phase. Genetic analysis identified the SLX4-binding partner MUS81 as a mediator of resistance to proton radiation. Both proton irradiation and olaparib treatment resulted in a similar prolonged accumulation of RAD51 foci in SLX4/MUS81-deficient cells, suggesting a common defect in the repair of DNA replication fork-associated damage. CONCLUSIONS: A defect in the FA pathway at the level of SLX4 results in hypersensitivity to proton radiation, which is, at least in part, due to impaired MUS81-mediated processing of replication forks that stall at clustered DNA damage. In vivo and clinical studies are needed to confirm these findings in human cancers.
PURPOSE: Clinical proton beam therapy has been based on the use of a generic relative biological effectiveness (RBE) of ∼1.1. However, emerging data have suggested that Fanconi anemia (FA) and homologous recombination pathway defects can lead to a variable RBE, at least in vitro. We investigated the role of SLX4 (FANCP), which acts as a docking platform for the assembly of multiple structure-specific endonucleases, in the response to proton irradiation. METHODS AND MATERIALS: Isogenic cell pairs for the study of SLX4, XPF/ERCC1, MUS81, and SLX1 were irradiated at the mid-spread-out Bragg peak of a clinical proton beam (linear energy transfer 2.5 keV/μm) or with 250 kVp x-rays, and the clonogenic survival fractions were determined. To estimate the RBE of the protons relative to cobalt-60 photons (Co60Eq), we assigned a RBE(Co60Eq) of 1.1 to x-rays to correct the physical dose measured. Standard DNA repair foci assays were used to monitor the damage responses, and the cell cycle distributions were assessed by flow cytometry. The poly(ADP-ribose) polymerase inhibitor olaparib was used for comparison. RESULTS: Loss of SLX4 function resulted in an enhanced proton RBE(Co60Eq) of 1.42 compared with 1.11 for wild-type cells (at a survival fraction of 0.1; P<.05), which correlated with increased persistent DNA double-strand breaks in cells in the S/G2 phase. Genetic analysis identified the SLX4-binding partner MUS81 as a mediator of resistance to proton radiation. Both proton irradiation and olaparib treatment resulted in a similar prolonged accumulation of RAD51 foci in SLX4/MUS81-deficient cells, suggesting a common defect in the repair of DNA replication fork-associated damage. CONCLUSIONS: A defect in the FA pathway at the level of SLX4 results in hypersensitivity to proton radiation, which is, at least in part, due to impaired MUS81-mediated processing of replication forks that stall at clustered DNA damage. In vivo and clinical studies are needed to confirm these findings in humancancers.
Authors: Jennifer M Svendsen; Agata Smogorzewska; Mathew E Sowa; Brenda C O'Connell; Steven P Gygi; Stephen J Elledge; J Wade Harper Journal: Cell Date: 2009-07-10 Impact factor: 41.582
Authors: Yonghwan Kim; Gabriella S Spitz; Uma Veturi; Francis P Lach; Arleen D Auerbach; Agata Smogorzewska Journal: Blood Date: 2012-10-23 Impact factor: 22.113
Authors: Anderson T Wang; Taeho Kim; John E Wagner; Brooke A Conti; Francis P Lach; Athena L Huang; Henrik Molina; Erica M Sanborn; Heather Zierhut; Belinda K Cornes; Avinash Abhyankar; Carrie Sougnez; Stacey B Gabriel; Arleen D Auerbach; Stephen C Kowalczykowski; Agata Smogorzewska Journal: Mol Cell Date: 2015-08-06 Impact factor: 17.970
Authors: Nicole Grosse; Andrea O Fontana; Eugen B Hug; Antony Lomax; Adolf Coray; Marc Augsburger; Harald Paganetti; Alessandro A Sartori; Martin Pruschy Journal: Int J Radiat Oncol Biol Phys Date: 2013-11-13 Impact factor: 7.038
Authors: John Peter McPherson; Bénédicte Lemmers; Richard Chahwan; Ashwin Pamidi; Eva Migon; Elzbieta Matysiak-Zablocki; Mary Ellen Moynahan; Jeroen Essers; Katsuhiro Hanada; Anuradha Poonepalli; Otto Sanchez-Sweatman; Rama Khokha; Roland Kanaar; Maria Jasin; M Prakash Hande; Razqallah Hakem Journal: Science Date: 2004-06-18 Impact factor: 47.728
Authors: Moritz Birkelbach; Natalie Ferraiolo; Liliana Gheorghiu; Heike N Pfäffle; Benedict Daly; Michael I Ebright; Cheryl Spencer; Carl O'Hara; Johnathan R Whetstine; Cyril H Benes; Lecia V Sequist; Lee Zou; Jochen Dahm-Daphi; Lisa A Kachnic; Henning Willers Journal: J Thorac Oncol Date: 2013-03 Impact factor: 15.609
Authors: Qin Zhou; Michelle E Howard; Xinyi Tu; Qian Zhu; Janet M Denbeigh; Nicholas B Remmes; Michael G Herman; Chris J Beltran; Jian Yuan; Patricia T Greipp; Judy C Boughey; Liewei Wang; Neil Johnson; Matthew P Goetz; Jann N Sarkaria; Zhenkun Lou; Robert W Mutter Journal: Cancer Res Date: 2021-02-17 Impact factor: 12.701
Authors: S P Ingram; J W Warmenhoven; N T Henthorn; E A K Smith; A L Chadwick; N G Burnet; R I Mackay; N F Kirkby; K J Kirkby; M J Merchant Journal: Sci Rep Date: 2019-04-23 Impact factor: 4.379